Home
/
Dianthus Therapeutics, Inc. /DE/
/
Financials
/
Quarterly
Dianthus Therapeutics, Inc. /DE/ — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Dianthus Therapeutics, Inc. /DE/ filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$396.0K
Nov 5, 2025
Q2
2025
Jun 30, 2025
$193.0K
Aug 7, 2025
Q1
2025
Mar 31, 2025
$1.16M
May 12, 2025
Q3
2025
Sep 30, 2024
$2.17M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$1.86M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$874.0K
May 12, 2025
Q3
2020
Sep 30, 2020
$0
Nov 5, 2020
Q2
2020
Jun 30, 2020
$0
Aug 6, 2020
Q1
2020
Mar 31, 2020
$0
May 7, 2020
Q3
2020
Sep 30, 2019
$0
Nov 5, 2020
Q2
2020
Jun 30, 2019
$0
Aug 6, 2020
Q1
2020
Mar 31, 2019
$0
May 7, 2020
Q3
2019
Sep 30, 2018
$0
Nov 13, 2019
Q2
2019
Jun 30, 2018
$0
Aug 8, 2019
Q1
2019
Mar 31, 2018
$0
May 9, 2019
Q3
2018
Sep 30, 2017
$0
Nov 8, 2018
Q2
2018
Jun 30, 2017
$0
Aug 9, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$396.0K
Nov 5, 2025
Q2
2025
Jun 30, 2025
$193.0K
Aug 7, 2025
Q1
2025
Mar 31, 2025
$1.16M
May 12, 2025
Q3
2025
Sep 30, 2024
$2.17M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$1.86M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$874.0K
May 12, 2025
Q3
2023
Sep 30, 2023
$924.0K
Nov 9, 2023
Q3
2023
Sep 30, 2022
$1.17M
Nov 9, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($36.77M)
Nov 5, 2025
Q3
2025
Jun 30, 2025
($31.63M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($31.63M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
($29.51M)
Nov 5, 2025
Q1
2025
Mar 31, 2025
($29.51M)
May 12, 2025
Q2
2025
Mar 31, 2025
($29.51M)
Aug 7, 2025
Q3
2025
Sep 30, 2024
($25.17M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($17.61M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($17.61M)
Nov 5, 2025
Q1
2025
Mar 31, 2024
($13.75M)
May 12, 2025
Q2
2025
Mar 31, 2024
($13.75M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($13.75M)
Nov 5, 2025
Q3
2024
Sep 30, 2023
($14.76M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($11.14M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($11.14M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($7.09M)
May 9, 2024
Q2
2024
Mar 31, 2023
($7.09M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($7.09M)
Nov 7, 2024
Q2
2023
Dec 31, 2022
($76.50M)
Aug 3, 2023
Q1
2023
Dec 31, 2022
($76.50M)
May 15, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($40.29M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($34.93M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($33.18M)
May 12, 2025
Q3
2025
Sep 30, 2024
($29.90M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($22.20M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($17.84M)
May 12, 2025
Q3
2024
Sep 30, 2023
($15.76M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($11.78M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($7.68M)
May 9, 2024
Q3
2023
Sep 30, 2022
($8.25M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($18.08M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($23.83M)
May 15, 2023
Q3
2022
Sep 30, 2021
($18.25M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($17.61M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($18.70M)
May 16, 2022
Q3
2021
Sep 30, 2020
($18.38M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($20.01M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($21.24M)
May 6, 2021
Q3
2020
Sep 30, 2019
($22.64M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($19.34M)
Aug 6, 2020